January 15, 2020

January 16, 2020 ICER Webinar:  An introduction to the Institute for Clinical Economic Review (ICER) and Their Implications for New Sickle Cell Disease Treatments:  A Primer on the Issues on January 16, 2020, 2:00-3:00pm. We are pleased to share that the myth/fact sheet, the FAQs and the webinar invitation are live on

We welcome interested stakeholders, patients, advocates, caregivers and families to join a webinar providing information about the metric used to assess the value of health care treatments called the quality-adjusted life year or “QALY” as well as the primary organization conducting QALY-based value assessments called the Institute for Clinical Economic Review (ICER). Because ICER will assess the value of new sickle cell disease treatments in March, 2020, it is important for all stakeholders to understand QALYs, ICER and how those value assessments may be used by public and private payers in their decisions related to drug coverage and formularies.